Covaxin for children: robust safety, says study
The Hindu
Healthy children and adolescents in the 2-18 age group underwent tests, it says
The Bharat Biotech International Limited (BBIL) on Thursday announced that the BBV152 (Covaxin), its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated and immunogenic in paediatric subjects in phase II/III study.
The Bharat Biotech had conducted phase II/III, open-label and multi-centre studies to evaluate the safety, reactogenicity and immunogenicity of Covaxin in healthy children and adolescents in the 2-18 age group, it said in a press release.
Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “Covaxin’s clinical trial data from the paediatric population is very encouraging. Safety of the vaccine is critical for children and we are glad to share that Covaxin has now proven data for safety and immunogenicity in children. We have now achieved our goal of developing a safe and efficacious COVID-19 vaccine for adults and children.”
Capt. Brijesh Chowta, Dakshina Kannada MP, on Saturday urged Union Finance Minister Nirmala Sitharaman to facilitate speeding up of ongoing critical infrastructure works in the region, including Mangaluru-Bengaluru NH 75 widening, establishment of Indian Coast Guard Academy, and merger of Konkan Railway Corporation with the Indian Railways.
Udhayanidhi Stalin urges cadres to launch campaign for securing 200 seats in 2026 Assembly elections
Udhayanidhi Stalin urges DMK members to gear up for 2026 Tamil Nadu elections, aiming for 200 seats.